Veeva

Makes software that drug makers use to run medicine trials and sales.

Company Health

/100

Very healthy

A quick check of the business from its yearly reports (2023–2026). It doesn’t say whether the stock is a good buy.

Does it make money?

25 of 25 · Good

$28 of every $100 in sales was left as profit last year.

Is it growing?

21 of 25 · Good

Sales grew about 14% a year over the last 3 years.

Can it handle what it owes?

25 of 25 · Good

It could pay off everything it owes with less than a year of the cash its business brings in.

Who owns it

2 of 23 own it · 2 bought more lately

bought lately

owns it

doesn’t own it

Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Semper Augustus, Akre

Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners

From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Veeva’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $1.47 billion in the year to Jan 2021 to $3.20 billion in the year to Jan 2026, and it made a profit every year.

FY2026

Sales

$3.20 billion

Profit

$909 million

What it owns and what it owes

At the end of Jan 2026 it owned $8.98 billion, including $1.42 billion in cash, and owed $1.76 billion.

Key facts

From its yearly report for the year to Jan 2026.

Sales

$3.20 billion

Profit

$909 million

Cash in the bank

$1.42 billion

Everything it owes

$1.76 billion

Year ends

January

Money shown in

U.S. dollars

Latest yearly report

10-K, filed Mar 20, 2026

Figures from Veeva’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works